Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1982 3
1983 1
1984 1
1985 1
1986 3
1987 4
1988 5
1989 2
1990 2
1991 2
1994 1
1995 4
1997 1
1998 1
1999 1
2000 2
2001 1
2002 2
2003 5
2004 6
2005 5
2006 9
2007 5
2008 8
2009 7
2010 3
2011 4
2012 5
2013 3
2014 7
2015 5
2016 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
Scalp psoriasis.
Wozel G, Klein E, Mrowietz U, Reich K, Sebastian M, Streit V. Wozel G, et al. J Dtsch Dermatol Ges. 2011 Jan;9(1):70-4. doi: 10.1111/j.1610-0387.2010.07412.x. J Dtsch Dermatol Ges. 2011. PMID: 20374417 English, German. No abstract available.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Dapsone in dermatology and beyond.
Wozel G, Blasum C. Wozel G, et al. Arch Dermatol Res. 2014 Mar;306(2):103-24. doi: 10.1007/s00403-013-1409-7. Epub 2013 Dec 6. Arch Dermatol Res. 2014. PMID: 24310318 Free PMC article. Review.
Psoriatic arthritis: a diagnostic challenge?
Buder K, Wozel G. Buder K, et al. Among authors: wozel g. G Ital Dermatol Venereol. 2010 Jun;145(3):407-14. G Ital Dermatol Venereol. 2010. PMID: 20461048 Review.
[Eosinophilic dermatoses].
Wozel G. Wozel G. Hautarzt. 2007 Apr;58(4):347-59; quiz 360. doi: 10.1007/s00105-007-1318-9. Hautarzt. 2007. PMID: 17364206 Review. German.
[A decade of biologics in dermatology].
Wozel G, Meurer M. Wozel G, et al. Hautarzt. 2012 Apr;63 Suppl 1:53-8. doi: 10.1007/s00105-011-2296-5. Hautarzt. 2012. PMID: 22543947 Review. German.
Hypersensitivity reactions to dapsone: a systematic review.
Lorenz M, Wozel G, Schmitt J. Lorenz M, et al. Among authors: wozel g. Acta Derm Venereol. 2012 Mar;92(2):194-9. doi: 10.2340/00015555-1268. Acta Derm Venereol. 2012. PMID: 22307940 Free article. Review.
111 results